

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a solution of valsartan in methyl t-butyl ether; and
 - b) recovering valsartan amorphous form, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
2. (canceled)
3. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a mixture of water and a solvent selected from the group consisting of ethanol, DMF, acetone and mixtures thereof; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
4. (withdrawn) The process of claim 3, wherein precipitating is carried out by combining water as an anti-solvent with the solution of valsartan in the solvent.
5. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) preparing a solution of valsartan in a solvent selected from the group consisting of tetrahydrofuran, dioxane, ethanol, isopropanol, and diethyl ether; and
 - b) removing the solvent to obtain the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
6. (withdrawn) The process of claim 5, wherein removing is carried out by evaporation.
7. (canceled)
8. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) suspending valsartan in water to obtain amorphous valsartan; and

- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
9. (withdrawn) The process of claim 8, wherein the suspending step includes heating.
10. (canceled)
11. (canceled)
12. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
- a) acidifying a basic aqueous solution of valsartan, wherein the acidifying results in precipitation of amorphous valsartan; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
13. (withdrawn) The process of claim 12, wherein the acidifying results in a pH of from about 2 to about 5.
14. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
- a) heating valsartan in diisopropyl ether to obtain amorphous valsartan; and
 - b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
15. (canceled)
16. (canceled)
17. (previously presented) Amorphous form of valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
18. (canceled)
- 19-80. (canceled)
81. (withdrawn) A pharmaceutical composition comprising amorphous valsartan of claim 17, and a pharmaceutically acceptable excipient.
82. (withdrawn) A method for treating hypertension in a mammal comprising the step of administering the pharmaceutical composition of claim 81 to the mammal in need thereof.
83. (previously presented) Amorphous valsartan having a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.
84. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) precipitating amorphous valsartan from a mixture of water and a solvent selected from the group consisting of ethanol, DMF, acetone and mixtures thereof; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.
85. (withdrawn) The process of claim 84, wherein precipitating is carried out by combining water as an anti-solvent with the solution of valsartan in the solvent.
86. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
- a) preparing a solution of valsartan in a solvent selected from the group consisting of tetrahydrofuran, dioxane, ethanol, isopropanol, and diethyl ether; and
 - b) removing the solvent to obtain the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.
87. (withdrawn) The process of claim 86, wherein removing is carried out by evaporation.
88. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
- a) suspending valsartan in water to obtain amorphous valsartan; and
 - b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.
89. (withdrawn) The process of claim 88, wherein the suspending step includes heating.
90. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
- a) acidifying a basic aqueous solution of valsartan, wherein the acidifying results in precipitation of amorphous valsartan; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.
91. (withdrawn) The process of claim 90, wherein the acidifying results in a pH of from about 2 to about 5.

92. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) heating valsartan in diisopropyl ether to obtain amorphous valsartan; and
- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

93. (withdrawn) A pharmaceutical composition comprising amorphous valsartan of claim 83, and a pharmaceutically acceptable excipient.

94. (withdrawn) A method for treating hypertension in a mammal comprising the step of administering the pharmaceutical composition of claim 93 to the mammal in need thereof.